Skip to main content
Springer logoLink to Springer
. 2025 Apr 26;272(5):362. doi: 10.1007/s00415-025-13077-1

Correction: Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

Jon Rodríguez-Antigüedad 1,2,3,4, Saül Martínez-Horta 1,2,3,4, Arnau Puig-Davi 1,2,3,4, Andrea Horta-Barba 1,2,3,4, Javier Pagonabarraga 1,2,3,4, Teresa de Deus Fonticoba 5, Silvia Jesús 6, Marina Cosgaya 7, Juan García Caldentey 8, María Asunción Ávila-Rivera 9, Nuria Caballol 9, Inés Legarda 10, Jorge Hernández Vara 4,11, Iria Cabo 12, Lydia López Manzanares 13, Isabel González Aramburu 14, Víctor Gómez Mayordomo 15, Jessica González Ardura 16, Julio Dotor García-Soto 17, Carmen Borrué 18, Berta Solano Vila 19, María Álvarez Sauco 20, Lydia Vela 21, Sonia Escalante 22, Esther Cubo 23, Zebenzui Mendoza 24, Isabel Pareés 25, Pilar Sánchez Alonso 26, María G Alonso Losada 27, Nuria López Ariztegui 28, Itziar Gastón 29, Javier Ruíz Martínez 30, María Teresa Buongiorno 31, Carlos Ordás 32, Caridad Valero 33, Víctor Puente 34, Mónica Kurtis 35, Marta Blázquez Estrada 36, Pablo Martínez-Martín 4, Pablo Mir 4,6, Diego Santos-García 37,38; COPPADIS Study Group38, Jaime Kulisevsky 1,2,3,4,38,
PMCID: PMC12033119  PMID: 40285930

Correction: Journal of Neurology (2025) 272:246 10.1007/s00415-024-12808-0

In the original version of this article, abstract was missing and should have read

Background Parkinson’s Disease (PD)-associated subjective cognitive decline (PDSCD) is defined as cognitive complaints without objective cognitive impairment. Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment.

Methods The main objectives are to identify cognitive progression patterns and clinical predictors of worse cognitive decline within a large PD-SCD cohort with a 4-year follow-up. All patients belong to the prospective observational multicenter study COPPADIS.

Results A total of 198 PD-SCD subjects were analyzed. Mean age was 60.9, mean disease duration 5.2, and mean PD-Cognitive Rating Scale (PD-CRS) 97.6. Subjects were classified as Progressors if their Reliable Change Index was ≤ − 1.64 at year 4, and as non-Progressors if it was > − 1.64 (− 1.64 corresponded to − 16 on the PD-CRS). Progressors had significantly higher age, Movement Disorders Society-Unified PD Rating Scale (MDS-UPDRS) III, levodopa equivalent daily-dose, Non-Motor Symptom Scale total score, memory-related cognitive complaints, and prevalence of REM-sleep behavior disorder (RBD) at baseline. A linear mixed-effects model showed divergent cognitive trajectories between Progressors and non-Progressors (estimate = − 26.8; p < 0.001), with no differences in motor trajectories. In the binary regression model, age (OR = 1.09; p = 0.001), MDS-UPDRS III (OR = 1.05, p = 0.008), and RBD (OR = 2.55, p = 0.010) at baseline were independent predictors of cognitive progression.

Conclusions Subjects with PD-SCD do not consistently show cognitive decline, but rather exhibit a heterogeneous progression. Age, MDS-UPDRS III and RBD significantly increase the risk of a more aggressive cognitive phenotype. Future research on biomarkers will help explore additional cognitive predictors in PD-SCD.

The original article has been corrected.

Contributor Information

Jaime Kulisevsky, Email: jaime.kulisevsky@uab.cat.

COPPADIS Study Group:

A. D. Adarmes, M. Almeria, M. G. Alonso Losada, A. Alonso Cánovas, F. Alonso Frech, R. Alonso Redondo, I. Álvarez, M. Álvarez Sauco, A. Aneiros Díaz, S. Arnáiz, S. Arribas, A. Ascunce Vidondo, M. Aguilar, M. A. Ávila, N. Bernardo Lambrich, H. Bejr-Kasem, M. Blázquez Estrada, M. Botí, C. Borrue, M. T. Buongiorno, C. Cabello González, I. Cabo López, N. Caballol, A. Cámara Lorenzo, H. Canfield Medina, E. Carabajal Pendón, F. Carrillo, F. J. Carrillo Padilla, E. Casas, M. J. Catalán, P. Clavero, A. Cortina Fernández, M. Cosgaya, A. Cots Foraster, A. Crespo Cuevas, E. Cubo, T. de Deus Fonticoba, O. de Fábregues-Boixar, M. Díez-Fairen, J. Dotor García-Soto, E. Erro, S. Escalante, E. Estelrich Peyret, N. Fernández Guillán, P. Gámez, M. Gallego, J. García Caldentey, C. García Campos, C. García Díez, J. M. García Moreno, I. Gastón, M. P. Gómez Garre, V. Gómez Mayordomo, J. González Aloy, I. González-Aramburu, J. González Ardura, B. González García, M. J. González Palmás, G. R. González Toledo, A. Golpe Díaz, M. Grau Solá, G. Guardia, J. Hernández Vara, A. Horta-Barba, D. Idoate Calderón, J. Infante, S. Jesús, J. Kulisevsky, M. Kurtis, C. Labandeira, M. A. Labrador, F. Lacruz, M. Lage Castro, S. Lastres Gómez, I. Legarda, N. López Ariztegui, L. M. López Díaz, D. López Domínguez, L. López Manzanares, B. López Seoane, S. Lucas del Pozo, Y. Macías, M. Mata, G. Martí Andres, M. J. Martí, J. C. Martínez Castrillo, P. Martinez-Martin, D. McAfee, M. T. Meitín, Z. Mendoza Plasencia, M. Menéndez González, C. Méndez del Barrio, P. Mir, J. Miranda Santiago, M. I. Morales Casado, A. Moreno Diéguez, I. Muro García, V. Nogueira, A. Novo Amado, S. Novo Ponte, C. Ordás, J. Pagonabarraga, I. Pareés, B. Pascual-Sedano, P. Pastor, A. Pérez Fuertes, R. Pérez Noguera, A. Planas-Ballvé, L. Planellas, M. A. Prats, C. Prieto Jurczynska, V. Puente, M. Pueyo Morlans, A. Puig Daví, N. Redondo Rafales, L. Rodríguez Méndez, A. B. Rodríguez Pérez, F. Roldán, M. Ruíz De Arcos, J. Ruíz Martínez, P. Sánchez Alonso, M. Sánchez-Carpintero, G. Sánchez Díez, A. Sánchez Rodríguez, P. Santacruz, D. Santos García, J. C. Segundo Rodríguez, M. Seijo, M. Sierra Peña, B. Solano Vila, E. Suárez Castro, J. P. Tartari, C. Valero, L. Vargas, L. Vela, C. Villanueva, and B. Vives


Articles from Journal of Neurology are provided here courtesy of Springer

RESOURCES